Circle Biologics®, Inc. has announced a technological break-through in regenerative medicine – its Autologous Platelet Concentrator Platform (APC™). This innovative single device platform is the first of its kind to incorporate both autologous (patient derived) cell concentration and protein concentration in one point-of-care device.
The APC patented design (which has earned the US Food and Drug Administration’s 510(k) marketing approval from its Office of Cellular, Tissue and Gene Therapies for creation of Platelet Rich Plasma and concentrated Platelet Poor Plasma) is a two-chamber, closed system that allows the user to perform two processing steps without the risk of contamination or waste, typically associated with transferring fluids between devices.
According to Matthew Kyle, president of Circle Biologics, this device will bring significant benefits to the surgical and healing processes associated with Cardiosurgery, Orthopedics, Cosmetic Surgery and Dental care.
"While this is not the first platelet-rich plasma device on the market, it is the first to incorporate both patient derived cell and protein concentration in one," says Kyle. "It’s a technological advancement in treating the entire medical procedure, giving improved solutions for patients and providers."
With its unique insights to medical care, Circle Biologics is standardizing the process of patient derived, patient point of care bio-fluid and cellular preparation across several therapies (i.e., platelet-rich plasma, stem cell, and tissue enrichment/generation). Additionally, the company has developed solutions that address the entire procedure—from procurement to processing to delivery or implantation—with a streamlined combination of devices that spare cells, reduce outside exposure, and protect the user and recipient.
